GERN earnings analysis
What we found in GERN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Geron Corporation reported Q1 2026 results with revenue of $51.8 million, exceeding estimates and the previous year by 31%. Gross margin improved slightly, while EPS of -$0.01 reflected a notable decrease in losses compared to the same quarter last year. Management's commentary indicated ongoing challenges with commercialization despite positive revenue trends from their only product, RYTELO, for treating lower-risk MDS. They reiterated potential risks relating to regulatory scrutiny and competition.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Growth of 31%
- Revenue reached $51.8 million, up from $39.6 million in Q1 2025.
- EPS Loss Narrowed to -$0.01
- EPS improved from -$0.03 in Q1 2025.
- Positive Revenue Surprise of 2.43%
- Actual revenue of $51.8 million beat estimates of $50.5 million.
- Cost Containment Efforts
- Total operating expenses decreased by 8% to $51.7 million from $56.3 million.
- Cash Position Remains Strong
- Cash, cash equivalents, and marketable securities totaled $341 million as of March 31, 2026.
- Revised Cash Flow Outlook
- Despite increasing operational cash used to $62.9 million, improved revenue mitigated some concerns.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Dependence on RYTELO Sales
- Future profitability remains dependent on RYTELO's commercial success, which is still uncertain.
- Existing Lawsuits Could Incite Costs
- Ongoing legal matters may divert resources and result in financial liabilities.
- Regulatory Compliance Risks
- Potential challenges in maintaining regulatory approval, particularly for product safety and effectiveness.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
- Segment
- RYTELO Sales
What they said about what is next.
Management provided no explicit numeric guidance for future quarters.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 2, 2026
- Geron Corporation's 10-K filing for the year ending December 31, 2025, highlights a robust year marked by a significant increase in revenue from its FDA-approved therapy, RYTELO®, resulting in a total annual revenue of…
- 10-Q · November 7, 2025
- Geron Corporation reported Q3 results with revenue of $47M, falling short of the expected $53M and demonstrating a 67% rise from the prior year. The adjusted EPS loss improved slightly to -$0.03, reflecting operational…
- 10-Q · August 6, 2025
- Geron Corporation reported stronger-than-expected Q2 2025 results, with revenues of $49 million, up from $40 million in Q1 and significantly higher than Q2 2024's $882,000. The company continues to experience…
- 10-Q · May 7, 2025
- Geron Corporation reported Q1 2025 financial results showing revenues of approximately $39.6 million, primarily driven by product sales from its drug RYTELO. Although the gross margin decreased slightly to 97%, the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GERN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever